Lavie Bio Advances Biofungicide Toward Commercialization in U.S., Europe Trials
AgriBusiness Global
2023.11.08
Lavie Bio Ltd., a subsidiary of Evogene Ltd., and a leading ag biologicals company that develops microbiome-based, computational-driven biostimulant and biopesticide novel products, reports significant progress with its bio-fungicide LAV321, discovered and optimized using Lavie Bio’s Biology Driven Design (BDD) platform powered by Evogene’s MicroBoost AI tech-engine.
In 2023 Lavie Bio achieved positive results in a series of field trials conducted across Europe and the United States, focusing on assessing LAV321’s efficacy in safeguarding crops against downy mildew and late blight diseases.
Trials conducted across Europe achieved an impressive average efficacy rate of 60% against downy mildew in grapes. At Cornell University in New York, LAV321 demonstrated remarkable field trial results with a 97% efficacy rate against leaf disease and 53% against bunch disease. These findings establish LAV321 as a potent solution against fungal diseases, focusing on oomycetes class diseases, including downy mildew, late blight, and other blight diseases, all known for their destructive impact on crop yields.
Lavie Bio Ltd., a subsidiary of Evogene Ltd., and a leading ag biologicals company that develops microbiome-based, computational-driven biostimulant and biopesticide novel products, reports significant progress with its bio-fungicide LAV321, discovered and optimized using Lavie Bio’s Biology Driven Design (BDD) platform powered by Evogene’s MicroBoost AI tech-engine.
In 2023 Lavie Bio achieved positive results in a series of field trials conducted across Europe and the United States, focusing on assessing LAV321’s efficacy in safeguarding crops against downy mildew and late blight diseases.
Trials conducted across Europe achieved an impressive average efficacy rate of 60% against downy mildew in grapes. At Cornell University in New York, LAV321 demonstrated remarkable field trial results with a 97% efficacy rate against leaf disease and 53% against bunch disease. These findings establish LAV321 as a potent solution against fungal diseases, focusing on oomycetes class diseases, including downy mildew, late blight, and other blight diseases, all known for their destructive impact on crop yields.
Read more here.